How to tell if a stock market dip is turning into a crash

Reuters

GSK names Pfizer scientist Dormitzer as vaccines R&D head

“The importance of vaccines has never been clearer, and the pace of technological innovation has rarely been greater … Phil’s scientific expertise and significant experience … will be key to ensuring we remain a leader in this field,” said Hal Barron, GSK chief scientific officer and R&D president. Dormitzer’s appointment is also a coup for Chief Executive Emma Walmsley as she defends GSK against activist shareholders. GSK has so far focused on producing its adjuvant technology to boost the immune response of others’ vaccines, and has teamed up with companies such as Vir and CureVac to develop treatments and improved mRNA vaccines.